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Objective: Drug-related problems (DRP) produce high morbidity and mortality. It is therefore essential to
identify patients at higher risk of these events. This study aimed to validate a DRP risk score in a large
number of inpatients.
Material and methods: Validation of a previously designed score to identify inpatients at risk of experienc-
ing at least one DRP in a tertiary university hospital from 2010 to 2013. DRP were detected by a pharmacy
warning system integrated in the electronic medical record. The score included the following variables
associated with a higher risk of DRP: prescription of a higher number of drugs, greater comorbidity,
advanced age, specific ATC groups and certain major diagnostic categories.
Results: The study included a total of 52,987 admissions; of these, at least one DRP occurred in 14.9%.
After validation of the score (period range, 2010–2013: 0.746–0.764), the area under the curve (AUC)
was 0.751 (95% CI: 0.745–0.756).
Conclusions: This value is higher than those reported in other studies describing validation of risk scores.
The score showed good capacity to identify those patients at higher risk of DRP in a much larger sample of
inpatients than previously described in the literature. This tool allows optimization of drug therapy mon-
itoring in admitted patients.
 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug-related problems (DRP) have been defined as ‘‘an event or
circumstance involving drug therapy that actually or potentially
interferes with desired health outcomes” (PCNE, 2017). This is a
general term that can encompass distinct terms referring to drug
safety such as drug-related events, adverse reactions, and medica-
tion errors.
The DRP rates reported in the literature vary widely: figures for
DRP as a cause of admission range from 2% to 10.3% (Angamo et al.,2017; Kalisch et al., 2012; Runciman et al., 2003; Singh et al., 2011;
Pedrós et al., 2014), while in admitted patients ranges from 27.8%
(Urbina et al., 2014) to as high as 81% (Blix et al., 2004), with var-
ious intermediate values reported by other studies (33 DRP por 100
pacientes ingresados (Bedouch et al., 2009), 58% (Dequito et al.,
2011), 64.7% (Roten et al., 2010), 5.7–6.1% (Krähenbühl-Melcher
et al., 2007).
This variability is likely due to the distinct terms used, as well as
differences in types of hospital, the study population and age, type
of admission and the methods used to identify DRP in published
studies.
The use of specific drug groups during admission, such as opi-
oids, diuretics, anticoagulants, antimicrobials and/or drugs of the
cardiovascular system in general have frequently been implicated
in the development of DRP in admitted patients (Bates et al.,
1999; Bedouch et al., 2009; Bedouch et al., 2015; Blix et al.,
2004; Davies et al., 2009; Krähenbühl-Melcher et al., 2007; Viktil
et al., 2004). This is the result of greater complexity in certain dis-
eases (Franz et al., 2012; Masoudi and Krumholz, 2003; Wong
et al., 2011).
Table 1
Variables associated with DRP.
Variable OR (95% CI) Points
Age > 60 years 1.197 (1.051–1.364) 1
Charlson index  2 1.332 (1.183–1.499) 1
Number of drugs during
hospitalization > 10
3.335 (2.956–3.763) 3
MDC Others 1.393 (1.056–1.838) 1
MDC Nervous system 1.393 (1.002–1.937) 1
MDC Circulatory system 1.892 (1.400–2.557) 1
MDC Digestive system 1.393 (1.042–1.863) 1
MDC Musculoskeletal system and
connective tissue
1.937 (1.432–2.619) 1
MDC Kidney and urinary tract 1.616 (1.169–2.235) 1
ATC C: cardiovascular system 1.546 (1.352–1.769) 1
ATC H: hormone therapy 1.198 (1.050–1.367) 1
ATC J: systemic, anti-infectious therapy 1.913 (1.696–2.157) 1
ATC S: sensory organs 2.559 (1.717–3.814) 2
ATC V: various 2.181 (1.679–2.834) 2
DRP, drug-related problem; MDC major diagnostic category; ATC, Anatomical
Therapeutic Chemical classification system; OR, odds ratio.
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ity and mortality (Baena et al., 2014; Kongkaew et al., 2008; Nickel
et al., 2013; Patel and Zed, 2002; Singh et al., 2011; Zargarzadeh
et al., 2007). Thus, the mortality risk has been reported to be
1.88 (95% CI, 1.54–2.22) (Bates et al., 1997) during admission and
to increase hospital stay by 1.91–4.6 days, (Bates et al., 1997;
Classen et al., 1997) increasing costs by between $2262 and 4685
(Bates et al., 1997; Classen et al., 1997).
Several strategies have been associated with an increase inmed-
ication safety, such as the implementation of electronic prescription
and some integrated clinical decision support systems. These have
been associated with a decrease in the risk of medication errors
and adverse drug events (Ammenwerth et al., 2008; Prgomet
et al., 2017; Radley et al., 2013; Reckmann et al., 2009; Westbrook
et al., 2015), as well as cost reductions (Ahmed et al., 2016; Eslami
et al., 2008; Kaushal et al., 2006; Westbrook et al., 2015).
The identification of patients at higher risk of DRP is essential to
allow closer monitoring of their drug treatment and to reduce their
risk of experiencing a DRP (Davies et al., 2009; Khan, 2013;
Parameswaran Nair et al., 2016a, 2016b; Zopf et al., 2008).
The implementation of the Computerized Physician Order Entry
(CPOE) in the Hospital del Mar (Barcelona, Spain) was progressive,
beginning in 2007. The Pharmacy Service developed in 2009 a
score to identify inpatients at risk of a DRP and identified age,
polypharmacy, greater severity as measured by the Charlson score,
certain Anatomical Therapeutic Chemical (ATC) groups (https://
www.whocc.no/atc_ddd_index/, 2017) and some major diagnostic
categories as factors increasing the likelihood of a DRP during
admission (Urbina et al., 2014).
Given that this score was obtained in a limited cohort of
patients, the aim of this study was to test it in a larger cohort over
a longer period of time.
2. Material and methods
2.1. Study design
The present prospective cohort study was performed in patients
admitted to a 400-bed university hospital in Barcelona (Spain) dur-
ing a 4-year period.
This study was approved by an independent ethics committee
(Comitè Ètic d’Investigació Clínica del Parc de Salut Mar)
(2016/6576/I).
No additional informed consent was required.
2.2. Study period
In a previous study, a score was designed, based on patients
admitted to Hospital del Mar (Barcelona, Spain) in 2009 (Urbina
et al., 2014). In the present study, the score was validated in a
broader cohort of patients admitted during a 4-year period
(2010–2013).
2.3. Setting
Tertiary university hospital with 431 beds (413 conventional
beds plus 18 beds for critically-ill patients). The catchment area
of the hospital has around 300,000 inhabitants living in two urban
districts (http://www.bcn.cat/estadistica/catala/index.htm, 2017).
The services provided by the hospital encompass acute medical
and surgical care.
2.4. Patient population
To validate the score, the same exclusion criteria were adopted
as those used to design the score to identify patients at risk of aDRP (Urbina et al., 2014). Thus, we excluded patients admitted
directly to the critical care unit and/or those aged 18 years or
younger. Likewise, admissions to the emergency department with-
out hospital admission, or admission to the emergency department
observation unit or resuscitation unit were also excluded because
these units lacked the CPOE system in 2009.
The CPOE can be accessed by health professionals through the
computerized medical records system of the hospital. Within the
CPOE, there is a pharmacy DRP warning system that can be used
by the pharmacy service. Both the CPOE and the DRP warning sys-
tem have been previously described in detail (Urbina et al., 2014).
2.5. Drug-related problem-risk score
The present study used a previously designed score (Urbina
et al., 2014). To design the score, data were used from patients
admitted between January and August in 2009 to a tertiary univer-
sity hospital (training set). The variables associated with having at
least one DRP were identified by a multivariate binary logistic
regression model and were used to compute the DRP risk score.
This score was subsequently validated in a group of patients
admitted between September and December 2009 (validation
set). Currently, work is being carried out with the Informatics Ser-
vice for its implementation in the CPOE and its use as a tool for the
rapid and routine detection of DRP.
In agreement with the design of the score (Urbina et al., 2014),
the following variables were significantly associated with the risk
of DRP in inpatients: age older than 60 years (OR, 1.197), higher
comorbidity (OR, 1.183), a higher number of prescribed drugs
(OR, 3.335), diagnoses of some major diagnostic category (MDC)
(Averill et al., 2007) and the prescription of drugs from certain
ATC groups (Table 1).
2.6. Data collection
Admitted patients were classified according to whether they
had a DRP or not during admission. DRP were identified by a team
of clinical pharmacists through the CPOE.
Causes of DRP were considered according to the classification of
the Pharmaceutical Care Network Europe (event or circumstance
involving drug therapy that actually or potentially interferes with
desired health outcomes).
A consensus was reached among clinical pharmacists on the
identification of DRP raising the strongest doubts, in order to
reduce bias.
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inpatient: demographic data (age, gender), admission type (elec-
tive or urgent), MDC, admitting department (surgical or medical),
comorbidity assessed with the Charlson index (Charlson et al.,
1987), diagnosis-related group (DRG) weight (Averill et al., 2007),
the number of different drugs administered during admission,
and readmission (admission within 90 days of a previous admis-
sion). Drugs were classified according to the ATC classification sys-
tem (https://www.whocc.no/atc_ddd_index/, 2017).
2.7. Statistical analysis
For the descriptive analysis of the sample, absolute and relative
frequencies were calculated for categorical variables and the mean,
standard deviation, median and interquartile range were calcu-
lated for quantitative variables.
A bivariate analysis of the data was conducted to confirm or
refute the association between the presence of at least one DRP
during admission with respect to each of the variables analyzed.
For categorical variables, the chi-square test or the Fisher exact test
was employed, when appropriate. For quantitative variables, the
Student-test for independent variables or the non-parametric
Mann-Whitney U test was used, depending on the normality of
the distribution of the data. On the basis of the score designed in
a previous study (Urbina et al., 2014), we calculated the risk scores
for a DRP in each admission in a validation cohort. To determine
the discriminatory capacity of the score, the area under the curve
(AUC) was calculated, together with its 95% confidence interval,
for the study as a whole and for separate years. The value of the
marker defined as cut-off was determined by the maximum of
the Youden index (J = sensitivity + specificity  1).
A histogram is also presented of the percentage of DRP obtained
in each risk range of the score.
Statistical significance was set at P < 0.05. The statistical analy-
sis was carried out using the SPSS 18.0 statistical package (IBM
Corp., New York, United States).
3. Results
There were 68,406 admissions between 2010 and 2013. After
application of the exclusion criteria, the score was validated in
52,987 admissions corresponding to 34,672 patients (mean num-
ber of admissions per patient, 1.53 (Table 2). The mean age of
admitted patients was 60.4 years (SD: 19.6) (range: 18–109) and
26,274 (49.6%) were men. At least one DRP was identified in
7882 (14.9%) of the admissions, the mean number of DRP being
1.44 (SD: 0.91) in these admissions (Table 2).
Of the 34,672 patients, at least one DRP was identified in 6327
(18.2%). In these patients, the mean number of DRP was 1.79 (SD:
1.49) (Table 2).Table 2




Admissions with DRP (%) 2245 (17.8) 1
DRP per admission 1.48 (0.98) 1
Patients 9910 1
Patients with DRP (%) 1969 (19.9) 1
DRP per patient 1.69 (1.30) 1
Prescriptions 133,214 1
Prescriptions with DRP (%) 3747 (2.81) 2
Prescriptions per DRP 1.13 (0.36) 1
DRP, drug-related problem.During the study period, 569,896 prescriptions were registered,
with a mean of 10.76 prescriptions per admission (SD: 6.3). At least
one DRP was found in 13,014 (2.28%) prescriptions (Table 2).
The total number of DRP was 11,355 (Table 2). The main rea-
sons for these DRP were prescription errors due to incorrect use
of the CPOE (19.3%), incorrect dose selection (18.9%) (drug dose
too high (10.3%), drug dose too low (8.6%)), inappropriate drug-
drug or drug-food combinations (11.5%), and dose adjustment
according to renal function (8.2%) (Table 3).
Table 4 shows the bivariate analysis of the demographic and
clinical characteristics of hospitalized patients with at least one
DRP compared with those with no DRP.
After validation of the score, it matched with the validation
cohort (the AUC was 0.751 (95% CI: 0.745–0.756) with a cut-off
of 5, sensitivity and specificity of 77.70% (95% CI: 76.77–78.62)
and 60.98% (95% CI: 60.53–61.43), respectively, and Youden index
of 0.39 (95% CI: 0.38–0.40).
Fig. 1 shows the rate of drug-related problems (DRP) in admis-
sions according to the DRP-risk score in the study of the score
design (Urbina et al., 2014), and the DRP rate in admissions accord-
ing to the DRP-risk score in the present study.4. Discussion
The aim of the present study was to validate a risk score previ-
ously designed in a representative sample. Thus, the score was val-
idated in 52,987 inpatients. Validation of the score generated a
ROC curve with an AUC of 0.751 (95% CI: 0.745–0.756) (range for
the period 2010–2013: 0.746–0.764). This value is higher than
those reported in other studies describing validation of risk scores
(O’Connor et al., 2012; Onder et al., 2010; Parameswaran Nair et al.,
2016b; Tangiisuran et al., 2014). Thus, three different studies
reported AUC values of 0.73 (95% CI: 0.66–0.80) (Tangiisuran
et al., 2014), 0.70 (95% CI: 0.63–0.78) (Onder et al., 2010), 0.67
(95% CI: 0.56–0.78) (Parameswaran Nair et al., 2016b) and 0.62
(95% CI: 0.57–0.68) (O’Connor et al., 2012).
A systematic review evaluated the quality of DRP prediction
models in elderly inpatients (Stevenson et al., 2014). According
to the results, the four studies included (McElnay et al., 1997;
Onder et al., 2010; Tangiisuran et al., 2014; Trivalle et al., 2011)
presented DRP prediction models of limited quality and their appli-
cation in clinical practice was considered inadequate.
Given the limitations of the available models, a study is cur-
rently being carried out to develop a model to stratify adverse drug
reactions in older patients admitted to hospital in the United King-
dom (Stevenson et al., 2016).
The score used in this study identified the following risk factors
for experiencing at least one DRP: age older than 60 years, greater
comorbidity, a higher number of drugs, specific MDC, and certain
ATC groups as risk factors (Urbina et al., 2014).011 2012 2013
812 3046 2174
3,085 13,715 13,606
916 (14.6) 2132 (15.5) 1589 (11.7)
.47 (0.92) 1.43 (0.90) 1.37 (0.78)
0,186 10,710 10,701
674 (16.4) 1917 (17.9) 1442 (13.5)
.68 (1.20) 1.59 (1.17) 1.51 (1.00)
38,551 149,410 148,721
918 (2.11) 3687 (2.47) 2662 (1.79)
.13 (0.36) 1.15 (0.39) 1.20 (0.43)
Table 3




Prescription errors due to incorrect use of the CPOE 2188 (19.3)
Inappropriate combination of drugs, or drugs and food 1301 (11.5)
Drug dose too high 1174 (10.3)
Drug dose too low 976 (8.6)
Pharmacokinetic problem requiring dose adjustment (e.g. renal
impairment)
931 (8.2)
Prescribed drug not available in the hospital formulary 869 (7.7)
Inadequate dosage regimen frequency 860 (7.6)
Inappropriate duplication of therapeutic group or active
ingredient
546 (4.8)
Inappropriate drug form 306 (2.7)
Indication for drug-treatment not noticed 256 (2.3)
No evidence of effectiveness 210 (1.8)
Inappropriate drug (incl. contra-indicated or allergy) 179 (1.6)
No indication for drug 153 (1.3)
Excessive drug spectrum (overtreated condition) 136 (1.2)
Inadequate treatment duration 125 (1.1)
Inappropriate mode of administration 112 (1.0)
Inappropriate timing of administration 101 (0.9)
Inappropriate route of administration 53 (0.5)
Other DRP 879 (7.7)
CPOE: Computerized physician order entry.
Table 4
Bivariate analysis of the demographic and clinical characteristics of hospitalized









Male 4359 (55.3) 21,914 (48.6) <0.001







0 2351 (29.8) 23,167 (51.4) <0.001
1 1784 (22.6) 8712 (19.3)
2 3747 (47.5) 13,226 (29.3)
Admission (%)
Urgent 5390 (68.4) 27,674 (61.4) <0.001
Scheduled 2492 (31.6) 17,431 (38.6)
Admission (%)
Surgical 3249 (41.2) 26,476 (58.7) <0.001
Medical 4633 (58.8) 18,629 (41.3)
Readmission due to prior
admission (%)
1075 (13.6) 3394 (7.5) <0.001
DRG weight
Mean (SD)
1.76 (1.60) 1.18 (0.96) <0.001
Number of drugs during
hospitalization
Mean (SD)
16.24 (8.50) 9.80 (5.28) <0.001
Major diagnostic category
Circulatory system 1410 (17.9) 5778 (12.8) <0.001
Digestive system 923 (11.7) 6179 (13.7) <0.001
Musculoskeletal system and
connective tissue
877 (11.1) 3460 (7.7) <0.001
Respiratory system 1251 (15.9) 5339 (11.8) <0.001
Kidney and urinary tract 752 (9.5) 3451 (7.7) <0.001
Nervous system 513 (6.5) 2911 (6.5) 0.855
Hepatobiliary system and pancreas 550 (7.0) 3284 (7.3) 0.338
Pregnancy, childbirth and
puerperium
141 (1.8) 6206 (13.8) <0.001
Other 1465 (18.6) 8492 (18.8) 0.598
ATC group
A: alimentary tract and
metabolism
7555 (95.9) 40,830 (90.5) <0.001
B: blood and hematopoietic organs 7322 (92.9) 39,648 (87.9)
C: cardiovascular system 6215 (78.9) 23,321 (51.7)
D: dermatological therapy 1518 (19.3) 3067 (6.8)
G: genitourinary therapy
(including hormone therapy)
916 (11.6) 7450 (16.5)
H: hormone therapy 2983 (37.8) 9596 (21.3)
J: systemic, anti-infectious therapy 5661 (71.8) 21,148 (46.9)
L: antineoplastic therapy and
immuno-modulatory agents
607 (7.7) 1727 (3.8)
M: musculoskeletal system 4354 (55.2) 26,830 (59.5)
N: nervous system 7176 (91.0) 40,449 (89.7)
P: antiparasitic products,
insecticides and repellants
95 (1.2) 187 (0.4)
R: respiratory system 3512 (44.6) 9712 (21.5)
S: sensory organs 354 (4.5) 631 (1.4)
V: various 855 (10.8) 1.355 (3.0)
DRP, drug-related problem; MDC major diagnostic category; ATC, Anatomical
Therapeutic Chemical classification system.
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aiming to identify risk factors for medication-related events and
even the development of predictive models for these events
(Alhawassi et al., 2014; Onder et al., 2010; Stevenson et al., 2014;
Tangiisuran et al., 2014; Zopf et al., 2008).
Although the rate of medication-related events is higher among
the older population, their repercussion among inpatients in gen-
eral is not inconsiderable (Bates et al., 1997; Classen et al., 1997).
Therefore, the aim of our previous study was to design a risk score
that could be applied in the majority of inpatients, similar to other
studies that have evaluated risk factors for DRP (Bedouch et al.,
2015; Blix et al., 2004; Classen et al., 1997; Zopf et al., 2008).
A constant finding in several studies is that a higher number of
drugs is a risk factor for the development of DRP (Alhawassi et al.,
2014; Angamo et al., 2017; Blix et al., 2004; Davies et al., 2009;
O’Connor et al., 2012; Onder et al., 2010; Pedrós et al., 2014;
Tangiisuran et al., 2014; Trivalle et al., 2011; Urbina et al., 2014;
Zopf et al., 2008).
The DRP rate among inpatients in the present study was lower
than that reported in other studies (Bedouch et al., 2009; Blix et al.,
2004). Thus, a study of 8152 admitted patients identified a rate of
33 DRP per 100 admissions (1.71 DRP per patient) (Bedouch et al.,
2009) while another study of patients hospitalized in the rheuma-
tology and internal medicine units of 5 Norwegian hospitals
reported that 81% had at least one DRP with a rate of 2.1 DRP
per patient (Blix et al., 2004). A more recent systematic review,
however, has indicated an extremely wide range of DRP prevalence
rates among inpatients, oscillating between 0.03 and18 DRP per
patient (Basger et al., 2014).
One of the most frequent DRP were prescription errors due to
incorrect use of the CPOE. Its implementation has been associated
with the appearance of a different and highly frequent type of DRP
due to lack of familiarity with the complete set of applications of
this computerized tool (Campbell et al., 2006; Koppel et al., 2005,
Schiff et al., 2015). Thus, CPOE training courses are provided annu-
ally as a continual process for health professionals. In addition, a
commission acted as a consultant for any questions users might
have about the system. Other common types of DRP were interac-
tions and overdosing, similar to the results of other studies con-
ducted in French hospitals, in which the occurrence ofinteractions ranged between 12.6% and 16.7%, and overdosing
between 19.2% and 12.8% (Bedouch et al., 2008, 2012).
One of the limitations of the present study is that validation was
conducted in patients admitted to the same center. Because the
characteristics of CPOE systems and their integrated applications
may vary, this hampers extrapolation of the results to other centers
and/or settings.
Another limitation is the variability in the study sample. In fact,

























Study of the score design (n= 2,425) 
Present study (n= 7,882)
Fig. 1. Rate of drug-related problems (DRP) in admissions according to the DRP-risk score in the study of the score design and in the present study.
O. Ferrández et al. / Saudi Pharmaceutical Journal 26 (2018) 703–708 707Moreover, patients admitted in the emergency department
observation unit or resuscitation unit were not considered. This
fact limits extrapolation of the results in this group of patients.
5. Conclusions
In the present study, the score was validated in a much
larger number of patients than in previous reports and during
a 4-year period, increasing the value of the score as a
prediction tool.
Application of the score in hospitalized patients would help to
target those that need closer clinical pharmacy monitoring
because they are at higher risk of inpatient DRP. Given the con-
stant patient turnover in acute-stay hospitals, the use of the score
avoid missed DRP that could result in negative clinical
consequences.
As in other studies, the score remains to be implemented in
daily clinical practice. Its integration in the CPOE and is routine
application in hospitalized patients will allow the identification
of patients at higher risk of DRP.
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